World Journal of Dentistry

Register      Login

VOLUME 14 , ISSUE 5 ( May, 2023 ) > List of Articles


Co-existence of Odontogenic Myxoma and Fragile X Syndrome: A Rare Report and Review of Management Considerations

Rajanikanth B Rajaram, Mirunalini Gunasekaran, Dominic Augustine, Kavitha Prasad

Keywords : Case report, Fragile X syndrome, morbidity, odontogenic myxoma, pediatric patients, peripheral ostectomy

Citation Information : Rajaram RB, Gunasekaran M, Augustine D, Prasad K. Co-existence of Odontogenic Myxoma and Fragile X Syndrome: A Rare Report and Review of Management Considerations. World J Dent 2023; 14 (5):466-470.

DOI: 10.5005/jp-journals-10015-2242

License: CC BY-NC 4.0

Published Online: 02-08-2023

Copyright Statement:  Copyright © 2023; The Author(s).


Background and aim: The aim of this article is to report a rare case of odontogenic myxoma (OM) with concurrent fragile X syndrome (FXS). OM has a high rate of recurrence, which makes its management very significant. Case description: A 10-year-old male patient reported to the dental outpatient department (OPD) with a chief complaint of swelling on his right lower side of the face for 3 months. His medical history revealed “FXS” and epilepsy. The swelling was evident extra-orally, and on intraoral examination, it extended into the buccal vestibule on the right side from 44 to 47 regions. Radiographic examination revealed a well-defined radiolucency measuring 2 × 2 cm. On histopathological examination, a final diagnosis of OM was established. Excision of the lesion was performed under general anesthesia, and no recurrence has been noted yet. Conclusion: This is the first report in the literature on OM occurring in an FXS patient treated with enucleation and peripheral ostectomy. The existence of OM, FXS, and epilepsy is a challenging aspect to manage. Clinical significance: Oral surgical procedures in patients with FXS can be performed with a good prognosis. The presence of comorbidities and locoregional challenges should be addressed for optimum management outcomes.

  1. Ansari A, Thomas A, Bohra RB, et al. Recurrent myxoma of the maxilla: a rare case. Otolaryngol Case Rep 2019;10:1–4. DOI: 10.1016/j.xocr.2018.12.002
  2. Gupta S, Grover N, Kadam A, et al. Odontogenic myxoma. Natl J Maxillofac Surg 2013;4(1):81–83. DOI: 10.4103/0975-5950.117879
  3. Zimmerman DC, Dahlin DC. Myxomatous tumors of the jaws. Oral Surg Oral Med Oral Pathol 1958;11(10):1069–1080. DOI: 10.1016/0030-4220(58)90289-5
  4. Shivashankara C, Nidoni M, Patil S, et al. Odontogenic myxoma: a review with report of an uncommon case with recurrence in the mandible of a teenage male. Saudi Dent J 2017;29(3):93–101. DOI: 10.1016/j.sdentj.2017.02.003
  5. Chaudhary R, Agarwal V, Kaushik AS, et al. Involvement of myocyte enhancer factor 2c in the pathogenesis of autism spectrum disorder. Heliyon 2021;7(4):e06854. DOI: 10.1016/j.heliyon.2021.e06854
  6. Ciaccio C, Fontana L, Milani D, et al. Fragile X syndrome: a review of clinical and molecular diagnoses. Italian J Pediatr 2017;43(1):39. DOI: 10.1186/s13052-017-0355-y
  7. Salcedo-Arellano MJ, Dufour B, McLennan Y, et al. Fragile X syndrome and associated disorders: Clinical aspects and pathology. Neurobiol Dis 2020;136:104740. DOI: 10.1016/j.nbd.2020.104740
  8. Heulens I, Suttie M, Postnov A, et al. Craniofacial characteristics of fragile X syndrome in mouse and man. Eur J Hum Genet 2013;21(8):816–823. DOI: 10.1038/ejhg.2012.265
  9. Friedrich RE, Kohlrusch FK, Luebke AM. Symptomatic mandibular fibrous dysplasia with concurrent triple X-and premutation stage fragile-X-syndrome: case report with short literature survey. Anticancer Res 2019;39(12):6769–6780. DOI: 10.21873/anticanres.13892
  10. Sabbagh-Haddad A, Haddad DS, Michel-Crosato E, et al. Fragile X syndrome: panoramic radiographic evaluation of dental anomalies, dental mineralization stage, and mandibular angle. J Appl Oral Sci 2016;24(5):518–523. DOI: 10.1590/1678-775720160170
  11. Ray P, Singh A, Dash JK, et al. Fragile X syndrome: a rare case report with unusual oral features. Contemp Clin Dent 2017;8(4):650–652. DOI: 10.4103/ccd.ccd_550_17
  12. Rajaratnam A, Shergill J, Salcedo-Arellano M, et al. Fragile X syndrome and fragile X-associated disorders. F1000Res 2017;6:2112. DOI: 10.12688/f1000research.11885.1
  13. Lozano R, Rosero CA, Hagerman RJ: Fragile X spectrum disorders. Intractable Rare Dis Res 2014;3(4):134–146. DOI: 10.5582/irdr.2014.01022
  14. Hagerman R, Hagerman P. Advances in clinical and molecular understanding of the FMR1 premutation and fragile X-associated tremor/ataxia syndrome. Lancet Neurol 2013;12(8):786–798. DOI: 10.1016/S1474-4422(13)70125-X
  15. Lucá R, Averna M, Zalfa F, et al. The fragile X protein binds mRNAs involved in cancer progression and modulates metastasis formation. EMBO Mol Med 2013;5(10):1523–1536. DOI: 10.1002/emmm.201302847
  16. Gurney ME, Cogram P, Deacon RM, et al. Multiple Behavior Phenotypes of the Fragile-X Syndrome Mouse Model Respond to Chronic Inhibition of Phosphodiesterase-4D (PDE4D). Sci Rep 2017;7(1):14653. DOI: 10.1038/s41598-017-15028-x
  17. Sherman S, Pletcher BA, Driscoll DA. Fragile X syndrome: diagnostic and carrier testing. Genet Med 2005;7(8):584–587. DOI: 10.1097/01.gim.0000182468.22666.dd
  18. Saldarriaga W, Tassone F, González-Teshima LY, et al. Fragile X syndrome. Colomb Med (Cali) 2014;45(4):190–198.
  19. Salti L, Rasse M, Al-Ouf K. Maxillofacial radiographic study of gardner's syndrome presenting with odontogenic myxoma: a rare case report. Stomatologija 2018;20(2):59–64.
  20. Kaufmann WE, Kidd SA, Andrews HF, et al. Autism spectrum disorder in fragile X syndrome: cooccurring conditions and current treatment. Pediatrics 2017;139(Supplement 3):S194–206. DOI: 10.1542/peds.2016-1159F
  21. Castagnola S, Bardoni B, Maurin T. The search for an effective therapy to treat fragile X syndrome: dream or reality? Front Synap Neurosc 2017;9:15. DOI: 10.3389/fnsyn.2017.00015
  22. Pittenger C, Bloch MH. Pharmacological treatment of obsessive-compulsive disorder. Psychiatr Clin North Am 2014;37(3):375–391. DOI: 10.1016/j.psc.2014.05.006
  23. Boffano P, Gallesio C, Barreca A, et al. Surgical treatment of odontogenic myxoma. J Craniofac Surg 2011;22(3):982–987. DOI: 10.1097/SCS.0b013e3182101400
  24. Augustine D, Sekar B, Saravannan S, et al. Myxoma of mandible –a case report with literature review. Int J Clin Den Sci 2014;5(1):17–19.
  25. Singh P, Nambiar KS, Rao RS, et al. A pediatric odontogenic myxoma of the maxilla: a case report and review. J Adv Clin Res Insights 2018;5(3):88–91. DOI: 10.15713/ins.jcri.219
  26. Augustine D, Rao RS, Kumar V, et al. Odontogenic myxoma with displaced third molar to coronoid process: role of differential stains to assess biologic behavior. World J Dent 2020;11(5):431–435. DOI: 10.5005/jp-journals-10015-1739
  27. Li TJ, Sun LS, Luo HY. Odontogenic myxoma: a clinicopathologic study of 25 cases. Arch Pathol Lab Med 2006;130(12):1799–1806. DOI: 10.5858/2006-130-1799-OMACSO
  28. Sato H, Kurihara Y, Shiogama S, et al. Long-term follow-up after conservative surgical treatment of odontogenic myxoma: a case report and literature review. Case Rep Dent 2019;2019:1634842. DOI: 10.1155/2019/1634842
  29. Chrcanovic BR, Gomez RS. Odontogenic myxoma: an updated analysis of 1,692 cases reported in the literature. Oral Dis 2019;25(3):676–683. DOI: 10.1111/odi.12875
  30. Saalim M, Sansare K, Karjodkar FR, et al. Recurrence rate of odontogenic myxoma after different treatments: a systematic review. Br J Oral Maxillofac Surg 2019;57(10):985–991. DOI: 10.1016/j.bjoms.2019.09.005
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.